Prostate Cancer Series: Understanding the Treatment Process

 

New Jersey CyberKnife is committed to helping patients understand their diagnosis and the treatment process. The video below provides an overview of how CyberKnife® treats prostate cancer and the benefits of using this advanced technology. This post is part of a series dedicated to addressing one of the most important health issues facing men today. […]

 

Learn More

 

 

ASTRO Endorses Stereotactic Body Radiation Therapy As First-Line Prostate Cancer Treatment Option

 

The American Society for Radiation Oncology has announced the classification of stereotactic body radiation therapy as a first-line treatment option for prostate cancer. As a first-line treatment, SBRT can be considered a primary form of treatment for prostate cancer. The results of long-term clinical trials supporting the safety and efficacy of stereotactic body radiation in […]

 

Learn More

 

 

Spotlight On: Prostate Cancer Foundation

 

The Prostate Cancer Foundation (PCF) is a dynamic organization committed to funding cutting-edge prostate cancer research. Since 1993, the PCF has funded more than 1,600 programs at nearly 200 research facilities around the world. In 2012, the organization raised a record $47 million and expanded their research programs to China. Each year, the PCF partners […]

 

Learn More

 

 

From the Doc: Benefits of CyberKnife for Prostate Cancer Patients

 

Find out how stereotactic body radiation therapy (SBRT) with CyberKnife® can benefit prostate cancer patients. Below are some advantages from our medical director Dr. David D’Ambrosio. What sets CyberKnife apart from other treatment options?CyberKnife offers patients a noninvasive treatment option that doesn’t impede on their lifestyle. CyberKnife can treat prostate cancer patients in five or […]

 

Learn More

 

 

Research Notes: High-dose Stereotactic Body Radiotherapy Effective, Quick for Localized Prostate Cancer

 

In a study presented at the annual meeting of the American Society of Radiation Oncology, researchers found that men with organ-confined prostate cancer can be treated successfully with stereotactic body radiation therapy. The five-year, multi-center study evaluated low-risk, intermediate-risk and high-risk patients for up to four years following treatment. At the five-year mark, the relapse-free […]

 

Learn More

 

 

New Jersey CyberKnife Develops Training Program for Multidisciplinary Approach to Lung Cancer Treatment

 

Lung cancer patients seeking treatment at New Jersey CyberKnife will soon experience a more collaborative approach to the planning and delivery of their treatment, including the participation of not only CyberKnife specialists, but also their referring doctors. New Jersey CyberKnife at the J. Phillip Citta Regional Cancer Center is developing a CyberKnife training program to […]

 

Learn More

 

 

New Jersey CyberKnife Medical Director Awarded Physician Excellence in Caring Award

 

Medical Director Dr. David D’Ambrosio was awarded the Physician Excellence in Caring Award by New Jersey CyberKnife hospital partner Community Medical Center for his commitment to enhancing patient care. He was honored not only for the lifelong bonds he develops with his patients, but also for his advocacy for access to state-of-the-art technology and willingness […]

 

Learn More

 

 

Prostate Cancer Series: What is Prostate Cancer?

 

Prostate cancer is a disease specific to men and develops in the prostate – a walnut-shaped organ in a man’s lower abdomen that controls the flow of urine and semen through the reproductive system. According to the Prostate Cancer Foundation, prostate cancer is typically a slow-growing tumor, often causing no symptoms until it reaches a […]

 

Learn More

 

 

Get to Know: New Jersey CyberKnife Medical Director Dr. David D’Ambrosio

 

Our medical director, Dr. David D’Ambrosio, has a longstanding commitment to clinical research and stereotactic radiosurgery for cancer treatment. He has given a number of national and international presentations at meetings of the American Society for Therapeutic Radiology and Oncology (ASTRO) and the American Radium Society (ARS). He has also published several peer-reviewed research papers […]

 

Learn More

 

 

Spotlight On: Prostate Cancer

 

New Jersey CyberKnife has opened a clinical trial in collaboration with the University of Pittsburgh to evaluate stereotactic body radiation therapy for low, intermediate and high-risk prostate cancer patients. Results from these trials will add to the body of clinical research examining stereotactic body radiation therapy for prostate cancer and will help doctors analyze effects and outcomes to improve prostate treatment protocols.

Stereotactic body radiation therapy is a noninvasive method of treating tumors throughout the body with high-dose, precisely targeted radiation beams, in five or fewer procedures. New Jersey CyberKnife is the only facility in Ocean County that offers this treatment using advanced CyberKnife® technology.

 

Learn More